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Abstract Early full-term pregnancy is the only recognized
factor able to prevent breast cancer. There are several
hypotheses to explain the mechanisms of this protection,
namely an altered hormonal milieu, a differentiation
process or a switch in stem cell properties. To explore
them, authors have been using animal models, mainly in
rodents. Hormonal administration with estrogen and prog-
esterone was the most widely used process to mimic the
mammary changes during pregnancy. We have recently
proposed that this enigmatic protective role of a full-term
birth in breast cancer is carried out by tumor inhibition
mediated by differentiated mammary epithelial cells. This
explanation may give a new perspective of breast cancer
prevention and treatment. 
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Introduction
There are several established epidemiological factors that
may influence breast cancer incidence, such as age, genet-
ics, reproductive history (including parity, menarche,
menopause and first pregnancy age and extent of lactation),
family history of malignancies, personal history of breast
disorders, place of residence, socioeconomic status, ethnic-
ity or radiation [1, 2]. Despite this variety, the only factor
that may reduce the lifetime breast cancer risk is an early
full-term pregnancy [3–5]. Although the exact mechanisms
remain unknown, there are various theories and experimen-
tal models that try to clarify breast refractoriness to car-
cinogenesis after early pregnancy. This review, aims to dis-
cuss them, starting from an epidemiological approach and
reflecting on future perspectives in this field. 
Epidemiology
Women who have a child before 20 years of age have a sig-
nificant decrease of about 50% in the risk of developing
breast tumors. Nevertheless, this risk is increased if they
are older when they have a first full-term birth, when com-
pared with the nulliparous [6]. Recent studies reveal that
longer intervals between age of menarche and age of first
birth are associated with an increased risk of hormonally
sensitive types of breast cancer [7]. 
This protective role of pregnancy is not immediate and
a transient increase after delivery was demonstrated. 
Recent meta-analysis has demonstrated that there is a
hormonal specificity in this pregnancy protection. Only
hormone responsive breast tumors, which express estrogen
receptors (ER) and progesterone receptors (PR), are sus-
ceptible to the beneficial effects of parity. Surprisingly,
although most of the studies state no parity effect in nega-
tive ER and PR tumors, some reveal an increased risk of
developing this molecular type of breast cancer after preg-
nancy [6]. Futhermore, the prolonged use of oral contra-
ceptives may increase the ER rate within the tumor tissue;
these can, therefore, be considered an indirect prognostic
factor. [8] 
The initial differentiation of epithelial cells during early
pregnancy is not sufficient to protect against breast cancer.
Although most of the studies demonstrate that aborted
pregnancies are not associated with a different risk for
breast cancer [9], some data show that there may be an
increased risk among women who have undergone a termi-
nation [6]. Otherwise, the main protective influence of par-
ity in breast cancer is the timing of the first full-term preg-
nancy rather than its occurrence per se. The association is
independent of the number of live births [10]. 
Some epidemiological studies have shown that pro-
longed breast-feeding offers some slight protection against
breast cancer risk [11]. 
Mechanisms for breast cancer protection
During a full-term pregnancy, the mammary gland under-
goes a maturation step in which cellular differentiation
occurs. After the delivery and lactation, in spite of the
gland regression, there are still some features of differenti-
ation which remain. The same occurrence is observed not
only in humans but also in rodents [12, 13]. 
Different theories have been developed to explain the
protective role of pregnancy. However, there are four main
schools of thought which enjoy some consensus and have
common aspects. 
The first theory places the most important role of this
parity protection in the hormonal changes, namely in estra-
diol, prolactin and growth hormone levels [14, 15]. The
second is based on the fact that pregnancy is associated
with a cellular differentiation which is maintained after
involution. It considers epithelial cells to have less ability
to proliferate and then become less susceptible to carcino-
genic stimulus [12]. The third hypothesis accepts the can-
cer stem cell theory [16]. It states that the protective role of
pregnancy in breast cancer is due to the decreased number
of mammary stem cells, with less epithelial precursors
which are potentially susceptible to malignant transforma-
tion [17]. Finally, once the protection is specific for the
positive ER tumors, it can be mediated by changes in the
estrogen responsiveness, either directly or paracrinally,
through ER dependent or independent mechanisms [6]. 
Altered hormonal milieu
One of the hypotheses is that the protective role of the
pregnancy is related to permanent changes in the hormon-
al environment [18, 19]. Both prolactin and growth hor-
mone (GH) circulating levels are reduced in parous when
compared to the aged-matched virgin (AMV) animals [19,
20]. According to some authors, this decrease reduces the
susceptibility to carcinogenic transformation by reducing
the levels of ER and epithelial growth factor receptors
(EGF-R) in the parous mammary gland [18]. 
Induction of differentiation
Some authors suggest that pregnancy and hormonal admin-
istration induces the differentiation of the mammary gland,
inhibiting cancer initiation because of the removal of can-
cer-susceptible cells [21–23]. Carcinogen agents could
only interact with the undifferentiated and highly prolifer-
ating mammary epithelium cells of the terminal ducts,
which are transformed to less mitotic alveolar cells after a
hormonal stimulation. Although this theory is very attrac-
tive, it does not explain why placental lactogen and per-
phenazine (a dopamine receptor inhibitor which releases
prolactin) do not protect against breast cancer, despite pro-
moting differentiation [11]. Furthermore, the parous invo-
luted gland has the same degree of differentiation as the
AMV gland. Thus, this hypothesis does not clearly explain
the difference in their behavior when submitted to carcino-
genic exposure. 
Cell fate hypothesis
According to the cell fate hypothesis, during adolescence,
the hormonal environment promotes a molecular switch in
stem cells, making them resistant to any carcinogenic stim-
ulus through persistent differences in signal transduction
pathways. Breast cancer would originate in undifferentiat-
ed terminal structures of the mammary gland (lobules type
1) that would contain stem cells 1, the target of the neoplas-
tic event. Early parity would produce a distinct type of
cells, stem cells 2, by a differentiation process of the mam-
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mary gland [24]. Despite differentiation, the mammary
epithelium remains capable of responding with prolifera-
tion to a given stimuli, such as a new pregnancy. Under
these circumstances, however, the cells that are stimulated
to proliferate would be those in structures that had already
been primed by the first cycle of differentiation. Therefore,
they are able to metabolize the carcinogen and repair the
induced DNA damage more efficiently than the cells of the
nulliparous gland, being then less susceptible to carcino-
genesis. However, if the shifting of stem cells 1 to stem
cells 2 has not been completed, a powerful enough carcino-
genic stimulus may overburden the system, thereby suc-
cessfully initiating a neoplastic process. This hypothesis
would explain the pregnancy blockage in carcinogen-
induced proliferation [25]. 
Experimental models
The rat has been used as an ideal model for mechanistic
studies about human breast cancer, namely to investigate
the protective role of pregnancy. First of all, we have
much information about the physiological role of hor-
mones in the development and carcinogenesis of the rat
mammary gland. Afterwards, in this animal species, pari-
ty prevents most of the mammary tumors and this can be
mimicked by hormonal administration. Finally, there are
many similarities between rat and human mammary
glands and adenocarcinomas [26]. Both radiation and var-
ious chemicals are potent carcinogens able to induce
mammary tumors in female rats. The most commonly
used carcinogens are 7, 12-dimethylbenzanthracene
(DMBA) [26] and methylnitrosourea (MNU) [27].
Although there are slight differences within strains, mam-
mary tumors can be induced in several inbred or outbred
rat strains, such as Sprague-Dawley (NSD), and 
Wistar-Furth (WF) rats. Female rats less than 55 days old
produce two or three times more carcinomas than older
rats 100 days old, demonstrating an age-related suscepti-
bility to mammary carcinogenesis. After this, most of the
mammary tumors arising at 50–55 days of age are ovari-
an-dependent carcinomas [26] and develop primarily from
terminal end buds and terminal ducts [26, 28–30],
although, in mature parous rats, mammary tumors are hor-
mone-independent carcinomas and originate in the ducts.
However, the carcinogenic mechanism and the progres-
sion of normal epithelium to intraductal hyper-
plasia/papilloma and carcinoma seem to be the same.
Almost none of the experimental models of breast cancer
present metastasis during the 3–6 months of the study’s
duration, with the exception of a few studies which report-
ed metastases in rats splenectomized prior to carcinogen
treatment [28, 31]. There are several mechanisms that
might prevent tumor formation, namely the suppression of
carcinogenesis or the blocking of cancer promotion. The
protection against breast cancer in experimental models
can be achieved, for instance, by the administration of a
combination of antioxidant micronutrients, avoiding those
tumors with better prognosis [32, 33]. Prevention of mam-
mary carcinogenesis can also be obtained by a single
pregnancy or by hormonal regimens comprising proges-
terone and estrogen or human chorionic gonadotropin
[11]. Since the protective role of pregnancy can not be
completely explained, there have been many experimental
models trying to demonstrate parity-induced protection,
either physiologically or by hormone administration. The
two main classical models are the pre-treatment and post-
treatment. In the first, there is an initial hormonal stimula-
tion after which the gland involutes. The carcinogen is
then administered to the hormone-treated and to the AMV
animal of the control group. In the second animal model,
rats are treated with the carcinogen and then exposed to
the hormonal stimulus for a certain period. Pregnancy,
both prior and following carcinogen exposure, reduces the
incidence of mammary tumor and the number of carcino-
ma per rat, and significantly prolongs the latency period.
There is a long-lasting protective effect of pregnancy,
which was present even when the carcinogen was admin-
istered 100–130 days after the parturition [11]. Lactation
following pregnancy does not seem to have any additive
effect in breast cancer suppression, although a small sam-
ple size study gave opposite results [34]. The effect of
interruption of pregnancy has also been studied in experi-
mental models, but two different studies gave diverging
results. One study shows that there is some small protec-
tion [35] while the other shows that a pregnancy interrupt-
ed at mid-term confers the same protection [36]. We con-
sider the first work to have more powerful data as the ani-
mal groups involved were much larger. 
Mice models
Although most of the experimental studies were performed
in rats, the protective effect of pregnancy has also been
demonstrated in mice. Initially, authors demonstrated that
carcinogenic induction was inhibited in lactating mice [37].
It was later shown that involuted parous mammary gland
was also unsusceptible to carcinogenic stimulus, although
a comparison with an AMV mice group to exclude the pos-
sibility of the age-related refractoriness was not made [20].
More recently, this comparison was carried out in BD2fF1
and C3H/Sm mice, showing that mice are also a good
model for studying pregnancy protection against breast
cancer [38]. 
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Hormonal mimicry of pregnancy
Pregnancy can be mimicked by hormonal treatment, either
by using estrogen and progesterone or by using human
chorionic gonadotropin [39], which is responsible for a rise
in endogenous sex steroids. Both models were, therefore,
used and were effective in reducing the incidence of mam-
mary tumors in rodents [40]. Several studies demonstrated
that, although there is a slight protection conferred by the
separate use of estrogen or progesterone, the full protective
effect is only achieved when both are used [11]. With
regards to the doses and duration of the hormonal adminis-
tration, we conclude that modest doses (20 μg estrogen and
20 mg progesterone) can be sufficient to prevent mamma-
ry carcinogenesis when administrated for 21 days in rats.
However, if we use lower doses or the same doses for
shorter periods of time, only partial protection is obtained
[41]. There is, therefore, available evidence that the dura-
tion of estrogen and progesterone treatment, as well as the
animal age, is an important factor in the protection against
breast cancer [42]. Chorionic tropin also has a dose-
dependent effect when administered for 21 days, before the
DMBA carcinogenic stimulus, with higher doses reducing
the incidence and the number of tumors per rat [43]. The
effect of estrogen and progesterone has been further stud-
ied in mice models with disrupted pathways [44]. As there
is an overexpression of the HER2/neu oncogene in up to
30% of breast cancer, this hormonal protective effect was
studied in mice overexpressing the referred gene (MMTV-
neu mice), revealing a reduction in the incidence of mam-
mary tumors of more than 60%. The p53 pathway is also
disrupted in breast cancer and both p53 dependent and
independent pathways are responsible for the hormonal
protection. Apoptosis and cell arrest are acute responses
mediated by p53 after carcinogenic stimulus, and increase
following progesterone and estrogen treatment [45].
Nevertheless, some authors demonstrated that p53 inde-
pendent pathways were also activated by exogenous hor-
mones, with a 70% reduction in the incidence of mamma-
ry tumor incidence, using p53-deficient mice [46]. This
preventive effect seems to be restricted to tumor progres-
sion, while preneoplastic lesions are still developing. Even
when the estrogen and progesterone treatment was given to
older mice (23–25 weeks old) the protective effect of the
hormonal administration was preserved. 
Future perspectives
A recent in vitro study showed that normal mammary
epithelial cells inhibit breast cancer cell growth. This
process was mediated by maspin and insulin growth factor-
binding protein (IGF-BP) [47]. We have developed an in
vivo model which corroborates these results (unpublished
data) showing that the protective role of pregnancy in
breast cancer may be carried out by the increase in the
number of differentiated epithelial cells which produce
inhibitory factors for the surrounding environment. After
carcinogenic stimulus in the mammary gland, we may find
carcinogen initiated cells. However, the promotion and the
progression are blocked by a previous pregnancy or by a
hormonal treatment [48]. According to our results, this
blockage is related to the inhibitory factors produced by the
differentiated epithelial cells, which are highly developed
in these circumstances. An understanding of these inhibito-
ry pathways may clarify the protective role of pregnancy in
breast cancer and also contribute to the development of
prevention and treatment strategies in the near future. 
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